Nutex Health Inc. (NUTX) Stock Price & Analysis
Nutex Health Inc. (NUTX) closed at USD 206.09 on Thursday, October 22, 2026, up 4.29% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 197.61; the Oct 22, 2026 session ranged USD 194.23–206.75 on volume of 129,770 shares. Market capitalization is $1.41B, with a 52-week range of USD 83.99–226.16 (NCM). Source: Nexqual, retrieved October 23, 2026 at 09:59 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NUTX.md
Key facts (NUTX)
- Last four reported quarters (through Jun 30, 2026): revenue $847M, net income $180M (21.2% margin), free cash flow $274M (SEC filings).
- Valuation: P/E 7.8x (avg 9.5x at the last 2 fiscal year-ends), EV/EBITDA 3.2x, net cash $166M.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $43K; 1 not under a Rule 10b5-1 plan ($43K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 288.2 (range 200–325).
- Total return with dividends: 1Y +75.7% vs S&P 500 +14.9%; 5Y -84.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 5.71, revenue estimate $215M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NUTX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $332M | $219M | $248M | $480M | $875M | $847M |
| Gross profit | $179M | $15.4M | $34.8M | $196M | $444M | — |
| Operating income | $170M | -$407M | -$31.8M | $131M | $276M | $364M |
| Net income | $133M | -$425M | -$45.8M | $52.1M | $70.8M | $180M |
| EPS (diluted) | $33.00 | -$100.36 | -$10.39 | $9.69 | $10.48 | — |
| Free cash flow | $137M | $36.0M | -$8.2M | $20.8M | $246M | $274M |
| Gross margin | 54.1% | 7.0% | 14.0% | 40.9% | 50.8% | — |
| Operating margin | 51.4% | -185.4% | -12.8% | 27.2% | 31.5% | 43.0% |
| Net margin | 40.0% | -193.7% | -18.5% | 10.9% | 8.1% | 21.2% |
| Revenue growth | +21.0% | -33.9% | +12.9% | +93.8% | +82.4% | — |
| Cash + short-term investments | $36.1M | $34.3M | $22.0M | $40.6M | $186M | — |
| Total debt | $89.0M | $35.6M | $37.1M | $36.9M | $42.5M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NUTX)
P/E 7.8x · P/S 1.7x · EV/EBITDA 3.2x · EV/Sales 1.5x · P/FCF 5.1x · P/B 3.6x · FCF yield 19.43% · Earnings yield 12.75% · Net cash $166M · EV $1.25B
P/E at fiscal year-ends: Dec 2025 15.7x, Dec 2024 3.3x.
Insider sales (SEC Form 4, open-market, last ~7 months) (NUTX)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Saunders Scott J | Director | 203 | $43K | 33.7% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (NUTX)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 288.2 (low 200, high 325).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-25 | Freedom Capital Markets | Target raised | Buy | $280 → $306 |
| 2026-09-04 | B. Riley Securities | Target raised | Buy | $290 → $325 |
| 2026-08-11 | Lake Street | Target raised | Buy | $235 → $310 |
| 2026-06-26 | B. Riley Securities | Initiated | Buy | $290 |
Total return (dividends reinvested) (NUTX)
| 1Y (from 2025-10-23) | 5Y (from 2022-04-04) | |
|---|---|---|
| Total return | +75.7% | -84.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +76.0% | -33.8% |
| Volatility (annualized) | 89.3% | 127.1% |
| Max drawdown | -54.3% (Dec 2025→Mar 2026) | -99.7% (May 2022→Jul 2024) |
NUTX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Hospital division revenue | $201.9M | 95.8% | -14.6% |
| Population health management division | $8.9M | 4.2% | +15.8% |
| Total revenue | $210.8M | 100% | — |
NUTX revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Hospital division revenue | $201.9M | 95.8% | -14.6% |
| Population health management division | $8.9M | 4.2% | +15.8% |
| Total revenue | $210.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
NUTX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Related party | Physician | “Certain of the Physician LLCs and Real Estate Entities are owned in part and, in some cases, controlled by related parties including members of our executive management team.” |
Quoted from the company's 10-K filed Mar 5, 2026.
NUTX company outlook (results filed Aug 6, 2026)
- “Based on current expectations, we anticipate the impact of these favorable changes will lead to an approximate 25-30% reduction in our normalized historical contract services expenses prospectively.”
- “When used in this press release, the words or phrases "will", "will likely result" "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.”
Quoted word-for-word from the SEC 8-K results press release.
NUTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $5.71 | $5.02 | +13.8% | $215.0M | 5 |
| Next quarter (ends Dec 2026) | $6.21 | $5.05 | +23.0% | $229.8M | 5 |
| Current fiscal year (ends Dec 2026) | $27.79 | $21.52 | +29.2% | $872.0M | 5 |
| Next fiscal year (ends Dec 2027) | $27.87 | $23.03 | +21.0% | $964.2M | 5 |
Key Statistics (as of October 23, 2026 at 09:59 UTC)
| Price | USD 206.09 |
|---|---|
| Change | ▲ 4.29% (up) |
| Previous Close | USD 197.61 |
| Open | USD 194.23 |
| Day Range | USD 194.23 – 206.75 |
| 52-Week Range | USD 83.99 – 226.16 |
| Volume | 129,770 shares |
| Market Cap | $1.41B |
| Exchange | NCM |
Technical Analysis (NUTX)
Nexqual's technical model rates NUTX "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:59 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 53.1 (neutral) |
| vs SMA50 | Above (USD 200.84) |
| MACD | -1.12 (negative) |
Analyst Ratings (NUTX)
Wall Street analysts rate NUTX "Buy" based on 5 analysts, with a mean price target of USD 288.2 (range USD 200–325), per Nexqual as of October 23, 2026 at 09:59 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 288.2 |
| High Target | USD 325 |
| Low Target | USD 200 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (NUTX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| Revenue Estimate | $214.98M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 9.38 vs est 4.95 ▲ beat |
| 2026-03-31 | USD 5.74 vs est 5.56 ▲ beat |
| 2025-12-31 | USD 1.62 vs est 5.56 ▼ miss |
| 2025-09-30 | USD 7.76 vs est 1.95 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
Financials & Fundamentals (NUTX)
| Total Revenue | $846.72M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -13.60% |
| Gross Margin | +54.51% |
| Operating Margin | +57.75% |
| Profit Margin | +21.25% |
| ROE | +64.56% |
| Debt / Equity | 0.68 |
| Current Ratio | 5 |
| Total Cash | $205.21M |
| Total Debt | $347.34M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $274.17M (32.4% of revenue) |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
Financial Health Score (NUTX)
Nexqual rates Nutex Health Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:59 UTC.
| Growth | Strong — Revenue +82% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55% (last 12 months) |
| Balance Sheet | Strong — $205M cash and investments vs $40M debt (Jun 2026, SEC), net cash |
| Cash Flow | Strong — FCF $274M (last 4 quarters to Jun 2026, SEC), 32% margin |
| Efficiency | Strong — ROE 65%, ROA 33.3% |
Ownership (NUTX)
| Insider Ownership | +29.23% |
|---|---|
| Institutional Ownership | +44.29% |
| Shares Outstanding | 6.85M |
| Float | 4.15M |
| Short % of Float | +28.94% |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
Leadership (NUTX)
Nutex Health Inc. is led by Thomas T. Vo, Chairman of the Board & CEO, per Nexqual as of October 23, 2026 at 09:59 UTC.
| Chairman of the Board & CEO | Thomas T. Vo |
|---|---|
| President & Director | Warren Hosseinion |
| Chief Financial Officer | Jon C. Bates |
| Chief Operating Officer | Wesley Bamburg FACHE |
| Director of Compliance | LaTanya Brackens |
Major Backers & Investors (NUTX)
Notable institutional backers of Nutex Health Inc. include Pertento Partners LLP, American Century Companies Inc, Shaw D.E. & Co., Inc., according to Nexqual as of October 23, 2026 at 09:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pertento Partners LLP | 6.59% |
| American Century Companies Inc | 3.47% |
| Shaw D.E. & Co., Inc. | 1.42% |
| UBS Group AG | 1.14% |
| Winmill & Co. Inc | 0.95% |
| Bexil Investment Trust | 0.91% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.95% |
| Vanguard Group | 3.15% |
| Geode Capital | 1.93% |
| State Street | 1.91% |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
From Nutex Health Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Based on the information and data we provide to HaloMD, using a proprietary data driven process, HaloMD submits the required documentation to the CIDRE through the federal portal.
- HaloMD, using proprietary data analysis and benchmarking, determines the appropriate offer amount on our behalf.
Legal & Regulatory Risks (Item 1A, quoted)
- We conduct business in a heavily regulated industry and if we fail to adhere to all of the complex government laws and regulations that apply to our business, we could incur fines or penalties or be required to make changes to our operations or experience adverse publicity, any or all of which could have a material adverse effect on our business, results of operations, financial condition, cash flows, and reputation.
- We face inspections, reviews, audits and investigations under federal and state government programs and contracts. These audits could have adverse findings that may negatively affect our business, including our results of operations, liquidity, financial condition and reputation.
- Changes to Stark Law DHS codes and exception thresholds may increase compliance risk.
- Risks Related to Our Common Stock
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PNTG | The Pennant Group, Inc. | USD 42.23 | ▲ 2.9% |
| USPH | U.S. Physical Therapy, Inc. | USD 88.73 | ▲ 2.84% |
| AGL | agilon health, inc. | USD 90.29 | ▼ 0.77% |
| INNV | InnovAge Holding Corp. | USD 9.52 | ▲ 4.16% |
| CMPS | COMPASS Pathways Plc - American | USD 11.63 | ▼ 1.77% |
| SNDA | Sonida Senior Living, Inc. | USD 33.87 | ▲ 1.2% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:59 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt